Defining, Treating, and Understanding Chronic Kidney DiseaseA Complex Disorder

被引:14
作者
Campbell, Dean [1 ]
Weir, Matthew R. [2 ]
机构
[1] Univ Maryland, Sch Med, Dept Internal Med, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Med, Div Nephrol, Baltimore, MD 21201 USA
关键词
GLOMERULAR-FILTRATION-RATE; BLOOD-PRESSURE CONTROL; SERUM URIC-ACID; CONVERTING ENZYME-INHIBITORS; STAGE RENAL-DISEASE; CARDIOVASCULAR-DISEASE; METABOLIC-ACIDOSIS; BARDOXOLONE METHYL; MYOGENIC RESPONSE; RECEPTOR BLOCKERS;
D O I
10.1111/jch.12560
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Chronic kidney disease (CKD) is prevalent in more than 20 million people in the United States. The majority of care provided to patients with this disease comes from primary care physicians, although it is often poorly understood. After an extensive literature review, it is clear that it can be difficult to classify and there are many barriers to care. Risk factors for both incident CKD and disease progression include hypertension, poor glycemic control, sociodemographic factors, acute kidney injury, metabolic acidosis, and possibly hyperuricemia and dietary factors. Treatment of patients with CKD should focus on mitigating risk factors, as well as common comorbidities such as cardiovascular disease, anemia, and bone mineral disease. Novel therapies such as pirfenidone, pentoxifylline, and endothelin-1 antagonists are being investigated with promising results. (C) 2015 Wiley Periodicals, Inc.
引用
收藏
页码:514 / 527
页数:14
相关论文
共 83 条
  • [81] Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease - Results from the AASK trial
    Wright, JT
    Bakris, G
    Greene, T
    Agodoa, LY
    Appel, LJ
    Charleston, J
    Cheek, D
    Douglas-Baltimore, JG
    Gassman, J
    Glassock, R
    Hebert, L
    Jamerson, K
    Lewis, J
    Phillips, RA
    Toto, RD
    Middleton, JP
    Rostand, SG
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (19): : 2421 - 2431
  • [82] Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
    Yale, J-F
    Bakris, G.
    Cariou, B.
    Yue, D.
    David-Neto, E.
    Xi, L.
    Figueroa, K.
    Wajs, E.
    Usiskin, K.
    Meininger, G.
    [J]. DIABETES OBESITY & METABOLISM, 2013, 15 (05) : 463 - 473
  • [83] Diabetic nephropathy
    Zelmanovitz, Themis
    Gerchman, Fernando
    Balthazar, Amely P. S.
    Thomazelli, Fulvio C. S.
    Matos, Jorge D.
    Canani, Luis H.
    [J]. DIABETOLOGY & METABOLIC SYNDROME, 2009, 1